Mark J. Rosenblum
2022 - Flex Pharma
In 2022, Mark J. Rosenblum earned a total compensation of $494.6K as Executive Vice President, Finance and Chief Financial Officer at Flex Pharma, a 12% increase compared to previous year.
Compensation breakdown
| Option Awards | $84,579 |
|---|---|
| Salary | $300,000 |
| Stock Awards | $97,775 |
| Other | $12,200 |
| Total | $494,554 |
Rosenblum received $300K in salary, accounting for 61% of the total pay in 2022.
Rosenblum also received $84.6K in option awards, $97.8K in stock awards and $12.2K in other compensation.
Rankings
In 2022, Mark J. Rosenblum's compensation ranked 4,355th out of 5,753 executives tracked by ExecPay. In other words, Rosenblum earned more than 24.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,355 out of 5,753 | 24th |
Division Manufacturing | 2,448 out of 3,133 | 22nd |
Major group Chemicals And Allied Products | 1,184 out of 1,419 | 17th |
Industry group Drugs | 1,112 out of 1,320 | 16th |
Industry Pharmaceutical Preparations | 811 out of 966 | 16th |
Source: SEC filing on November 1, 2024.
Rosenblum's colleagues
We found one more compensation record of an executive who worked with Mark J. Rosenblum at Flex Pharma in 2022.
2022
David and
Flex Pharma